flow trial semaglutide Ozempic® (semaglutide injection) Semaglutides Are Poised to Remake

Introduction to GLUD1, the gene that encodes GDH The human GDH cDNAs was first cloned and published by Nakatani et al

Other Key Findings Metabolic improvements: Participants saw reductions in A1C (for those with prediabetes or diabetes), fasting glucose, and triglycerides Liver fat reduction: Retatrutide reduced liver fat by up to 50%, which is why Eli Lilly added a NASH-specific trial to the Phase 3 program Side effects: Mostly gastrointestinal (nausea, diarrhea, constipation), similar to other GLP-1 drugs but manageable with slow titration Discontinuation rate: About 10% of participants stopped due to side effects, comparable to tirzepatide and semaglutide Study limitation: The Phase 2 trial was only 48 weeks long

These benefits make it especially appealing to individuals facing exposure to pollution, poor dietary habits, or chronic stress

Most GLP-1 medication protocols involve gradual dose escalation over several weeks or months